Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1. It is taken by mouth. Technically, rucaparib is an orally bioavailable small-molecule inhibitor that targets PARP1 and PARP2 catalytic activity and promotes PARP trapping on damaged DNA, which increases DNA single-strand breaks and converts them to lethal double-strand breaks in cells with homologous recombination deficiency such as BRCA1 or BRCA2 mutant tumors. It is approved for treatment and maintenance indications in certain ovarian and related gynecologic cancers and for select BRCA-mutant metastatic castration-resistant prostate cancer; the recommended adult dose for many approved indications is 600 mg orally twice a day, subject to dose adjustments for toxicity and hepatic impairment. Key clinical considerations include hematologic toxicities including anemia and thrombocytopenia, gastrointestinal effects, and transaminase elevations, and clinical use requires baseline and periodic monitoring of blood counts and liver function.
Typical pharmaceutical control strategy for rucaparib drug substance and drug product defines assay and impurity acceptance criteria established during development in line with ICH Q3A and Q3B guidance; a common specification target is an assay not less than 98.0 percent w/w and limits for individual unspecified impurities at or below 0.10 percent w/w with a total unspecified impurity limit commonly set at or below 0.5 to 1.0 percent w/w depending on toxicological qualification. Known related substances from synthetic route and degradation pathways such as N-oxidation products, dealkylated derivatives, ring-opened species and residual starting materials are identified, qualified and assigned higher individual limits when toxicology permits, typically in the 0.1 to 0.5 percent range for qualified impurities. Control measures include validated synthetic steps, in-process controls, crystallization/purification to reduce related compounds, and accelerated stability studies to define impurity profiles over shelf life.
Rucaparib is used as a targeted anti-cancer therapy for adults with certain BRCA-mutated cancers and for maintenance therapy in recurrent epithelial ovarian, fallopian tube and primary peritoneal cancers that respond to platinum-based chemotherapy; it also has regulatory approval for selected patients with deleterious BRCA-mutant metastatic castration-resistant prostate cancer. Specific indication, eligibility and treatment lines depend on regional approvals and labeling.
Cost varies widely by source, availability, import status and whether a branded or generic formulation is supplied; rucaparib is an oncology specialty drug and out-of-pocket costs can be substantial. For an accurate current price obtain quotes from hospitals, specialty pharmacies or authorized distributors in India and check for patient assistance programs or government schemes that may reduce cost.
Rucaparib is neither classic cytotoxic chemotherapy nor immunotherapy; it is a targeted small-molecule PARP inhibitor that exploits defects in tumor DNA repair machinery to induce cancer cell death, and is categorized as targeted therapy.
Rucaparib inhibits PARP enzymes, primarily PARP1 and PARP2, blocking poly-ADP ribosylation required for repair of single-strand DNA breaks and promoting PARP trapping on DNA; in cells deficient in homologous recombination repair, such as those with BRCA1 or BRCA2 loss, this leads to accumulation of DNA damage, replication fork collapse and synthetic lethal cell death.
